ViroCell Biologics, founded in the UK by a prolific academic viral vector manufacturing team, has officially launched. Viral vectors are the primary delivery method for innovative vaccines such as the Oxford/Astra Zeneca COVID vaccine, as well as enabling inputs for the manufacture of the rapidly growing Cell and Gene Therapy sector (CGT).
ViroCell aims to be the supplier of choice for viral vectors and gene modified cells, to academic and corporate clients, for translational cell and gene therapies going into clinical trials. ViroCell has assembled an experienced viral vector manufacturing team to support its heavy operational demand and is now building out further manufacturing capability to address the current, acute supply chain bottlenecks worldwide. ViroCell is deploying significant capital and management talent around the viral vector design and manufacturing track record of Farzin Farzaneh, PhD – professor of molecular medicine at King’s College London, and expects to employ more than 50 professionals in the UK by the end of 2021.
Meeting the Demand for Viral Vectors in the UK
The fast-growing demand in viral vectors for clinical trials makes clear the pressing need for a highly experienced commercial Contract Development and Manufacturing Organization (CDMO) that can leverage the best of the UK’s world-leading heritage by investing in new capacity, to design and deliver viral vectors for clinical trials faster and more reliably.
The curative potential seen from the first wave of approved CGTs, is driving new company formation and external investment into therapies heading for clinical trial. The ViroCell team has contributed to innovative therapies to combat childhood inherited genetic diseases from muscular dystrophy to lysosomal storage disorders; and in adult acquired diseases from leukemia to solid tumors.
ViroCell is negotiating with world-leading teaching hospitals and universities to bring more clean room facilities for the production of viral vectors in the UK. The company, an innovation driven CDMO, founded in 2020 by the Truell Conservation Foundation and serial biotech entrepreneur, John W. Hadden II, has market leading cell and gene therapy expertise and decades of experience in oncology innovation through its world-class Scientific Advisory Board (SAB).
SAB Chairman Ferid Murad, MD, PhD, co-winner of the 1998 Nobel Prize in Medicine, said, “I am delighted to chair this accomplished group and to help ViroCell innovate to support the advancement of the cell and gene therapy community.”
In addition to Farzin Farzaneh and Ferid Murad, the SAB has embraced eminent leaders in the field:
Evren Alici, MD, PhD - Senior researcher and group leader in Hematology at Karolinska Institutet (KI), Department of Medicine, Stockholm, Sweden and co-director of NextGenNK, an international Competence Center for the development of next-generation NK cell-based cancer immunotherapies
Jean-Pierre Bizzari, MD – SAB member of the French National Cancer Institute (INCa) and European Organization of Research and Treatment of Cancer (EORTC) and Chairman of the New Drug Advisory Committee. He was formerly Executive Vice-President, Group Head, Clinical Oncology Development (U.S., Europe, and Asia/Japan) at Celgene from 2008 to 2015
Mark Lowdell, PhD – Professor of Cell and Tissue Therapy at University College London and director of Cellular Therapy at the Royal Free London NHS Foundation Trust
Peter Harper, MD – Medical Oncologist, founder of the Oncology Department at Guy's and St Thomas' NHS Foundation Trust, the London Oncology Clinic, and Welbeck Health Partners
Paul G. Richardson, MD – Clinical program leader and director of clinical research, Jerome Lipper Multiple Myeloma Center, Dana Farber Cancer Institute, and RJ Corman Professor of Medicine, Harvard Medical School
Comments from Leadership
Edmund Truell, chairman of the Truell Conservation Foundation, said, “We have been studying the viral vector supply-demand imbalance with great interest. We believe that the shortage of highly specialized design and manufacturing capacity and the UK’s hitherto uncommercial attitude to new vector innovation, represents a clear barrier to gene therapy innovation. Following the remark...
(All Rights Reserved)